Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC
Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
How Can Cancer Cachexia Be Treated? Molecular Subtypes May Be Key
Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.
